Patient organizations and support infrastructure¶
All principal links below were checked on the organizations' own websites on 2026-08-30. These resources supplement local clinical, emergency, psychosocial, financial, and legal services; they do not replace them.
Quick directory¶
| Organization | Geography | Patient-facing functions | Research / advocacy function | Verified source |
|---|---|---|---|---|
| GO2 for Lung Cancer | United States; national | Help line, peer support, treatment and trial navigation, educational material | Screening, stigma and research advocacy; community engagement | GO2 help line |
| LUNGevity Foundation | United States; international digital reach | Education, biomarker information, peer communities, caregiver and survivorship material | Research funding, patient-focused research, policy advocacy | Patients and caregivers |
| Lung Cancer Research Foundation | United States; digital reach | Education, support line, caregiver resources, navigation | Research funding and public advocacy | How we can help |
| Roy Castle Lung Cancer Foundation | United Kingdom | Helpline, practical and emotional support, information, community | Prevention, early diagnosis and policy advocacy; research support | Roy Castle |
GO2 for Lung Cancer¶
GO2 offers a support and navigation entry point that spans diagnosis, treatment, clinical trials, peer connection, survivorship, and caregiving. Its explicit stigma work is relevant to LUSC because the histology is strongly associated with tobacco exposure and patients may anticipate blame before care. The organization describes stigma as a barrier to screening, help-seeking, treatment, and hope (GO2 stigma resource).
Use case: a person needs a navigator, peer contact, a structured question list, or help locating a trial. Re-check whether the service covers the person's country and whether language or phone costs create barriers.
LUNGevity Foundation¶
LUNGevity provides a broad educational hub for patients and care partners, including biomarker information and survivorship resources. Its structure is useful when a patient has been told that "squamous cancers do not have mutations": the more accurate message is that actionable alterations are less common, testing policies vary, and trial eligibility may still depend on profiling.
Use case: biomarker education, preparing for an oncology discussion, caregiver education, peer support, or research participation. Educational material should be reconciled with the treating jurisdiction's current guideline and formulary.
Lung Cancer Research Foundation¶
The Lung Cancer Research Foundation combines patient information and support with a research-funding mission. Its patient resource hub can orient people who need reliable introductory material and caregiver support without presuming a specific treatment pathway.
Use case: general education, support navigation, caregiver material, or learning about research. It is not an emergency triage line.
Roy Castle Lung Cancer Foundation¶
Roy Castle provides UK-focused practical and emotional support, a helpline, information, and advocacy around prevention and earlier diagnosis. Its national context makes it particularly useful alongside NHS pathways and UK benefits or service navigation.
Use case: UK-specific support, helpline contact, prevention and symptom-awareness information, or advocacy. Treatment decisions still belong with the multidisciplinary clinical team.
What a complete referral should specify¶
| Need | Minimum handoff information |
|---|---|
| Peer support | Diagnosis/stage if the person wants to share it, language, preferred format, privacy preferences |
| Trial navigation | Histology, stage, prior therapies, PD-L1, molecular results, performance status, geography and travel limits |
| Financial navigation | Insurance or health-system context, transport, lodging, work and caregiving constraints |
| Caregiver support | Caregiver's own needs, consent boundaries, urgent symptom plan, respite options |
| Survivorship | Treatment received, persistent symptoms, recurrence plan, smoking-cessation support, rehabilitation needs |
| Bereavement | Preferred contact, cultural and spiritual needs, local crisis and grief resources |
Verification and safety notes¶
- Service listings are date-stamped, not guaranteed permanent.
- A national organization may be able to educate but not provide local financial or legal advice.
- Trial-matching results are leads for clinician and registry confirmation, not eligibility determinations.
- Do not send personally identifying health information through an unverified web form.
- For haemoptysis, severe breathlessness, stridor, neurological deficits, fever with neutropenia, or suspected immune toxicity, use the clinical emergency pathway described in red flags and safety concerns.
Evidence context¶
The need for navigation is supported by studies of diagnostic-pathway experience ([PMID 18197868](https://pubmed.ncbi.nlm.nih.gov/18197868/){target="_blank" rel="noopener"}; [PMID 36710377](https://pubmed.ncbi.nlm.nih.gov/36710377/){target="_blank" rel="noopener"}), trial barriers ([PMID 18650170](https://pubmed.ncbi.nlm.nih.gov/18650170/){target="_blank" rel="noopener"}; [PMID 22591607](https://pubmed.ncbi.nlm.nih.gov/22591607/){target="_blank" rel="noopener"}), and unmet needs in underserved populations ([PMID 35696628](https://pubmed.ncbi.nlm.nih.gov/35696628/){target="_blank" rel="noopener"}). Organizations address parts of this gap; their existence is not evidence that access is adequate.